CAMTA2

Across TCGA pan-cancer cohorts, CAMTA2 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated CAMTA2 data layer compared with 6 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CAMTA2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAMTA2 expression acts as an unfavorable survival marker, although some lineages such as PAAD and BRCA show a favorable association.

ACC, PAAD, and LUSC are the cancer types where CAMTA2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.206	0.681	<.001	85	view →
PAAD	DFS	Median	All	0.579	0.391	<.001	83	view →
LUSC	DFS	Tertile	II,III,IV	0.267	0.509	.004	55	view →
BRCA	OS	Median	III,IV	0.887	0.770	.004	36	view →
KIRC	DFS	Tertile	All	0.764	0.507	.009	27	view →
KICH	OS	Quartile	II,III,IV	0.451	1.000	.003	17	view →
DLBC	DFS	Tertile	All	0.536	0.939	.004	15	view →
LUAD	OS	Median	All	0.779	0.629	.003	13	view →
MESO	OS	Median	III,IV	0.482	0.633	.024	12	view →
CHOL	OS	Quartile	All	0.348	1.000	.013	9	view →
READ	DFS	Tertile	IV	0.304	0.774	.006	9	view →
UVM	DFS	Tertile	III,IV	1.000	0.310	.026	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

CAMTA2–ACC (DFS)

Open the ACC breakdown →